CLINICAL TRIALS PHASE 3

 

INTRODUCTION: Efficacy and adverse drug reactions monitoring:  Researchers plan Phase 3 studies to prove whether a product deals an action benefit to a specific people or not. Sometimes known as pivotal studies, these studies comprise 300 to 3,000 volunteers. Phase 3 studies deliver most of the safety data. The previous study might not be able to detect less common side effects. But phase 3 studies are conducted on large number of volunteers and longer in duration, the results are more probable to detect long-term or uncommon side effects. Around 25-30% of drugs travel to the next phase of clinical research. If a drug developer has data from its previous tests, preclinical and clinical trials that a drug is safe and effective for its intended use, then the industry can file an application to market the medicine. The FDA review team comprehensively inspects all submitted data on the drug and makes a conclusion to approve or not to approve it.

NEW DRUG APPLICATION: A New Drug Application (NDA) expresses the full story of a drug molecule. Its purpose is to verify that a drug is safe and effective for its proposed use in the people studied. A drug developer must include all about a drug starting from preclinical data to Phase 3 trial detain the NDA. Developers must include reports on all studies, data, and analysis. Beside with clinical trial outcomes, developers must include Proposed labeling, Safety updates, Drug abuse information, Patent information, Institutional review board compliance information, Directions for use.

FDA Review: Once FDA obtains a complete NDA then FDA team of review may require about 6 to 10 months to take a pronouncement on whether to approve the NDA. If FDA governs that a drug has been revealed to be safe and effective for its proposed use, it is then essential to work with the developer for upgrade prescribing information. This is denoted as labeling. Labeling precisely defines the basis for approval and direction how to use the drug. Although, remaining issues required to be fixed before the drug to be approved for marketing. In other cases, FDA have need of additional studies. At this situation, the developer can choose whether to continue further development or not. If a developer distresses with an FDA decision, there are tools for official appeal.

RELATED;

1.  CLINICAL TRIALS PHASE I

2.  CLINICAL TRIALS PHASE II

3.  CLINICAL TRIALS PHASE 4  

4.  STUDY DESIGNS  

REFERENCES